SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (27232)1/6/1999 1:46:00 PM
From: Hippieslayer  Read Replies (1) | Respond to of 32384
 
Biotech stock prices respond to only one thing....the streets perception that the compnay will make money on their drugs once approved. CLtr is a good example. Bexxar works...and works quite well.
No one on the street looks to be jumping over roofs for lgnd. Panretin and Ontak will most likely get final approval but they are not "big time drugs like Epo and Neupo at amgen. Lgnd has to show wall st the money before wall st will bid up the price.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News